Travere Therapeutics Inc (TVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Sales | 37,095 | 32,196 | 30,888 | -21,269 | 28,075 |
| Cost of Goods | 1,289 | 1,452 | 4,145 | -883 | 1,114 |
| Gross Profit | 35,806 | 30,744 | 26,743 | -20,386 | 26,961 |
| Operating Expenses | 128,680 | 135,147 | 124,257 | 84,359 | 109,679 |
| Operating Income | -92,585 | -103,951 | -97,369 | -105,628 | -82,604 |
| Interest Expense | 2,821 | 2,843 | 2,850 | 2,698 | 2,829 |
| Other Income | 6,177 | 4,927 | 3,733 | 3,987 | 1,515 |
| Pre-tax Income | -89,229 | -101,867 | -96,486 | -104,339 | -83,918 |
| Income Tax | 12 | 65 | 78 | 63 | 145 |
| Net Income Continuous | -89,241 | -101,932 | -96,564 | -104,402 | -84,063 |
| Net Income Discontinuous | 239,976 | 16,302 | 10,233 | 38,579 | 14,407 |
| Net Income | $150,735 | $-85,630 | $-86,331 | $-65,823 | $-69,656 |
| EPS Basic Total Ops | 1.97 | -1.13 | -1.27 | -1.03 | -1.09 |
| EPS Basic Continuous Ops | -1.17 | -1.34 | -1.42 | -1.63 | -1.31 |
| EPS Basic Discontinuous Ops | 3.14 | 0.21 | 0.15 | 0.61 | 0.22 |
| EPS Diluted Total Ops | 1.97 | -1.13 | -1.27 | -1.03 | -1.09 |
| EPS Diluted Continuous Ops | -1.17 | -1.34 | -1.42 | -1.63 | -1.31 |
| EPS Diluted Discontinuous Ops | 3.14 | 0.21 | 0.15 | 0.61 | 0.22 |
| EBITDA(a) | $-81,110 | $-93,004 | $-90,749 | $-98,717 | $-83,969 |